| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.LUNGCAN.2008.04.001 |
| P698 | PubMed publication ID | 18486273 |
| P2093 | author name string | Justin Stebbing | |
| Thomas Powles | |||
| Robin M Rudd | |||
| Paula Wells | |||
| Sarah Slater | |||
| Dean Fennell | |||
| Jonathan Shamash | |||
| Michael T Sheaff | |||
| Kirsty McPherson | |||
| Jeremy P C Steele | |||
| P433 | issue | 1 | |
| P304 | page(s) | 94-97 | |
| P577 | publication date | 2008-05-16 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma | |
| P478 | volume | 63 |
| Q37296603 | A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 |
| Q35994241 | A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol |
| Q47912434 | Advances in systemic therapy for malignant mesothelioma: future perspectives |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q38018217 | Asbestos-related pleuropulmonary diseases: benign and malignant |
| Q27851697 | BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. |
| Q64235291 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q83789589 | Chemotherapy for malignant pleural mesothelioma |
| Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
| Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
| Q38909086 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. |
| Q64285361 | Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q54698040 | Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. |
| Q28390399 | Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients |
| Q33645613 | Immunotherapy and radiation therapy for malignant pleural mesothelioma. |
| Q37457703 | Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. |
| Q91949972 | Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma |
| Q91123540 | Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial |
| Q83412919 | Malignant pleural mesothelioma |
| Q83466825 | Malignant pleural mesothelioma |
| Q59274199 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q57822522 | Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy |
| Q52672887 | Medical treatment of malignant pleural mesothelioma relapses. |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q35839385 | Mesothelioma: a review |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q93338919 | Product review: avelumab, an anti-PD-L1 antibody |
| Q91949964 | Relations between approved platinum drugs and non-coding RNAs in mesothelioma |
| Q38190418 | Role of microRNAs in malignant mesothelioma. |
| Q42864235 | Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006) |
| Q59796596 | Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report |
| Q37582256 | Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q53641990 | Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma. |
| Q90808650 | Tumour Treating Fields for mesothelioma: controversy versus opportunity |
| Q35129531 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
Search more.